Sugi Predict

Sugi Predict / Targets / BCOR

BCOR

BCL-6 corepressor (BCoR) · Q6W2J9 · BCOR on Sugi Atlas →

1,283 patent compounds predicted against BCOR, 727 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20772465 SCHEMBL20772465 0.53 10/20
SCHEMBL21786960 SCHEMBL21786960 0.51 10/20
SCHEMBL20772931 SCHEMBL20772931 0.69 9/20
SCHEMBL20773049 SCHEMBL20773049 0.51 9/20
SCHEMBL20773220 SCHEMBL20773220 0.51 6/20
SCHEMBL20775965 SCHEMBL20775965 0.74 5/20
SCHEMBL20772501 SCHEMBL20772501 0.71 5/20
SCHEMBL20773006 SCHEMBL20773006 0.57 5/20
SCHEMBL12863391 SCHEMBL12863391 0.54 5/20
SCHEMBL24430197 SCHEMBL24430197 0.47 5/20
SCHEMBL23249972 SCHEMBL23249972 0.84 4/20
SCHEMBL14179046 SCHEMBL14179046 0.65 4/20
SCHEMBL10338289 SCHEMBL10338289 0.46 4/20
SCHEMBL23249924 SCHEMBL23249924 0.70 3/20
SCHEMBL20773008 SCHEMBL20773008 0.61 3/20
SCHEMBL1842652 SCHEMBL1842652 0.60 3/20
SCHEMBL18190682 SCHEMBL18190682 0.60 3/20
SCHEMBL9036234 SCHEMBL9036234 0.58 3/20
SCHEMBL23250063 SCHEMBL23250063 0.57 3/20
SCHEMBL20772687 SCHEMBL20772687 0.57 3/20

Clinical trials — most relevant to BCOR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients PHASE3UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma PHASE3ACTIVE_NOT_RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients PHASE2COMPLETED
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT PHASE1/PHASE2COMPLETED
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer PHASE2COMPLETED
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders PHASE1/PHASE2COMPLETED
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation PHASE2UNKNOWN
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy nanUNKNOWN
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics nanCOMPLETED
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia nanCOMPLETED
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) nanRECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BCOR binder may also engage these)

ProteinNameSimilarity
Q8CGN4 — 1.000 Q8CGN4 →
Q3UHR0 — 0.999 Q3UHR0 →
Q69ZK6 — 0.999 Q69ZK6 →
Q8R5I7 — 0.997 Q8R5I7 →
Q5U5X8 — 0.997 Q5U5X8 →
Q7TPM1 — 0.997 Q7TPM1 →
Q5SYE7 — 0.997 Q5SYE7 →
P48552 — 0.997 P48552 →
KDM3B Lysine-specific demethylase 3B 0.996 landscape →
P21999 — 0.995 P21999 →
Q6ZPI3 — 0.995 Q6ZPI3 →
Q8BZ32 — 0.995 Q8BZ32 →
Q6PGH4 — 0.995 Q6PGH4 →
Q32N19 — 0.995 Q32N19 →
Q27IV2 — 0.995 Q27IV2 →
Q80WT2 — 0.995 Q80WT2 →
Q9ULH7 — 0.995 Q9ULH7 →
Q00900 — 0.994 Q00900 →
P35547 — 0.994 P35547 →
Q8CBD1 — 0.994 Q8CBD1 →
Q60988 — 0.994 Q60988 →
Q568E2 — 0.994 Q568E2 →
Q28BT7 — 0.994 Q28BT7 →
Q2KHR2 — 0.994 Q2KHR2 →
O15417 — 0.994 O15417 →
Q3UHF7 — 0.994 Q3UHF7 →
A6H5Y1 — 0.994 A6H5Y1 →
Q96JN0 — 0.994 Q96JN0 →
Q9BTA9 — 0.994 Q9BTA9 →
Q9CWL2 — 0.994 Q9CWL2 →